![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-business-update-302214993.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-option-and-license-agreement-for-potential-first-in-class-b7h3ptk7-topo-i-payload-bispecific-adc-program-with-biocytogen-302210790.html
https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302195126.html
https://www.prnewswire.com/news-releases/ideaya-announces-pricing-of-public-offering-302192746.html
https://www.prnewswire.com/news-releases/ideaya-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302192551.html
https://www.prnewswire.com/news-releases/ideaya-announces-investor-webcast-to-report-clinical-data-update-for-ide397-phase-2-monotherapy-expansion-dose-in-mtap-deletion-urothelial-and-lung-cancer-on-monday-july-8-2024-302190198.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide397-and-trodelvy-combination-in-mtap-deletion-bladder-cancer-302181366.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-clinical-program-updates-for-ide397-a-potential-first-in-class-phase-2-mat2a-inhibitor-targeting-mtap-deletion-solid-tumors-302179680.html
https://www.prnewswire.com/news-releases/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asco-and-clinical-update-for-phase-2-company-sponsored-neoadjuvant-study-302161137.html